Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 40:2006-2012
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thadani, U.
Right arrow Articles by Sundaresan, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thadani, U.
Right arrow Articles by Sundaresan, P.

CLINICAL STUDY

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease

Udho Thadani, MD, FACC*,*, William Smith, MD, FACC{dagger}, Stephen Nash, MD, FACC{ddagger}, Neville Bittar, MD, FACC§, Stephen Glasser, MD, FACC||, Puneet Narayan, MD, FACC, Richard A. Stein, MD, FACC#, Sharon Larkin, RN**, Arthur Mazzu, PhD**, Robert Tota, MD, FACC{dagger}{dagger}, Kenneth Pomerantz, PhD{ddagger}{ddagger} and Pavur Sundaresan, MD, PhD**

* Oklahoma University, Health Sciences Center, and Veterans Affairs Medical Center, Cardiology Section, Oklahoma City, Oklahoma, USA
{dagger} New Orleans Center for Clinical Research, New Orleans, Louisiana, USA
{ddagger} Syracuse Preventive Cardiology, Syracuse, New York, USA
§ Gemini Scientific, Madison, Wisconsin, USA
|| University of Minnesota, School of Public Health, Minneapolis, Minnesota, USA
Veterans Affairs Medical Center, Washington, DC, USA
# Brooklyn Hospital Center, Department of Cardiology, Brooklyn, New York, USA
** Bayer Corporation, Department of Clinical Pharmacology, West Haven, Connecticut, USA
{dagger}{dagger} Bayer Corporation, Department of Medical Affairs, West Haven, Connecticut, USA
{ddagger}{ddagger} Bayer Corporation, Department of Scientific Relations, West Haven, Connecticut, USA

Manuscript received May 15, 2002; revised manuscript received July 12, 2002, accepted July 24, 2002.

* Reprint requests and correspondence: Dr. Udho Thadani, OUHSC, Cardiology, 920 SL Young, WP 3120, Oklahoma City, OK 73104, USA.
udho-thadani{at}ouhsc.edu

OBJECTIVES: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited exercise time, time to first awareness of angina, and time to ischemic threshold (ST-segment depression ≥1 mm from baseline) during exercise tolerance testing (ETT) was examined in patients with stable coronary artery disease (CAD).

BACKGROUND: Erectile dysfunction (ED) is common among men with CAD. PDE5 inhibition is increasingly the preferred treatment option for ED. However, the effect of PDE5 inhibition on exercise-induced ischemia in CAD patients has received limited prospective evaluation.

METHODS: In this double-blind, crossover, single-dose multicenter study, 41 men with reproducible stable exertional angina due to ischemic CAD received vardenafil 10 mg or placebo, followed by ETT (5 to 10 metabolic equivalents [METS], Bruce protocol) 1 h postdose. Sublingual nitrate use was prohibited for ≥24 h pre- and postexercise study days. End points included symptom-limited treadmill exercise time, time to first awareness of angina, time to ischemic threshold, and safety.

RESULTS: Relative to placebo, vardenafil 10 mg did not alter exercise treadmill time (427 ± 105 s vs. 433 ± 109 s, p = 0.39), or time to first awareness of angina (292 ± 110 s vs. 291 ± 123 s, p = 0.59), but significantly prolonged time to ischemic threshold (334 ± 108 s vs. 381 ± 108, p = 0.0004). At peak exercise, vardenafil 10 mg did not alter blood pressure, heart rate, or rate-pressure product relative to placebo. The most common adverse events (facial flushing and headache) were of mild or moderate intensity, and short-lived.

CONCLUSIONS: Vardenafil 10 mg did not impair the ability of patients with stable CAD to exercise at levels equivalent or greater than that attained during sexual intercourse (average of 2.5 to 3.3 METS).

Abbreviations and Acronyms
  CAD
  coronary artery disease
  DBP
  diastolic blood pressure
  ECG
  electrocardiogram
  ED
  erectile dysfunction
  ETT
  exercise tolerance test
  METS
  metabolic equivalents
  MI
  myocardial infarction
  PDE5
  phosphodiesterase-5
  SBP
  systolic blood pressure




This article has been cited by other articles:


Home page
AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
J. W. M. Cheng and S. R. Berhane
Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors
American Journal of Lifestyle Medicine, May 1, 2009; 3(3): 201 - 211.
[Abstract] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
G. Jackson
CHAPTER 15c Erectile Dysfunction
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text]


Home page
Exp. Biol. Med.Home page
A. Caretti, P. Bianciardi, R. Ronchi, M. Fantacci, M. Guazzi, and M. Samaja
Phosphodiesterase-5 Inhibition Abolishes Neuron Apoptosis Induced by Chronic Hypoxia Independently of Hypoxia-Inducible Factor-1{alpha} Signaling
Experimental Biology and Medicine, October 1, 2008; 233(10): 1222 - 1230.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Eur. Respir. J., July 1, 2008; 32(1): 198 - 209.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D. A. Kass
Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans
Circulation, October 25, 2005; 112(17): 2642 - 2649.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
T. K. Thethi, N. O. Asafu-Adjaye, and V. A. Fonseca
Erectile Dysfunction
Clin. Diabetes, July 1, 2005; 23(3): 105 - 113.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. A. Kloner
Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction
Circulation, November 9, 2004; 110(19): 3149 - 3155.
[Full Text] [PDF]


Home page
J AndrolHome page
G. Pomara, G. Morelli, S. Pomara, S. Taddei, L. Ghiadoni, N. Dinelli, F. Travaglini, M. Dicuio, N. Mondaini, A. Salvetti, et al.
Cardiovascular Parameter Changes in Patients With Erectile Dysfunction Using Pde-5 Inhibitors: A Study With Sildenafil and Vardenafil
J Androl, July 1, 2004; 25(4): 625 - 629.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. Morgentaler
A 66-Year-Old Man With Sexual Dysfunction
JAMA, June 23, 2004; 291(24): 2994 - 3003.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. T. Russell, B. K. Khandheria, and A. Nehra
Erectile Dysfunction and Cardiovascular Disease
Mayo Clin. Proc., June 1, 2004; 79(6): 782 - 794.
[Abstract] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. M Crowe and D. S Streetman
Vardenafil Treatment for Erectile Dysfunction
Ann. Pharmacother., January 1, 2004; 38(1): 77 - 85.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. M. Fox, U. Thadani, P. T.S. Ma, S. D. Nash, Z. Keating, M. A. Czorniak, H. Gillies, M. Keltai, and on behalf of the CAESAR I investigators
Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina
Eur. Heart J., December 2, 2003; 24(24): 2206 - 2212.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Reffelmann and R. A. Kloner
Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease
Circulation, July 15, 2003; 108(2): 239 - 244.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Vardenafil and the Cardiovascular Response to Exercise
Journal Watch Cardiology, February 21, 2003; 2003(221): 6 - 6.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement